|Bid||32.00 x 900|
|Ask||49.40 x 1200|
|Day's Range||42.98 - 43.47|
|52 Week Range||29.17 - 43.51|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||11.72|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 17, 2019|
|1y Target Est||N/A|
RBC Capital analyst Frank Morgan maintained a Hold rating on Fresenius Medical Care (NYSE:FMS) Corp. on Thursday, setting a price target of $42, which is approximately 6.90% above the present share price of $39.29.
Is Fresenius Medical Care AG & Co. KGaA (ETR:FME) a good dividend stock? How can we tell? Dividend paying companies...
Image source: The Motley Fool. Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)Q1 2020 Earnings CallMay 6, 2020, 9:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by.
Healthcare companies worldwide have benefited from subsidies and increased demand as a result of the coronavirus crisis, but they have also faced new costs, including protective gear. Fresenius' first-quarter net income was 465 million euros ($503.97 million), above analysts' average forecast of 421.8 million euros, a Refinitiv poll found. "It is, however, too early to say with any certainty what impact COVID-19 will have on the company's full business year," Chief Executive Stephan Sturm said in a statement.
European shares opened little changed on Wednesday as a batch of mixed earnings reports and simmering U.S.-China tensions added to doubts about a swift economic recovery even as many countries eased lockdown measures. The pan-European STOXX 600 index was flat as losses in oil and gas sector, following a recent surge, offset gains in healthcare shares. The global mood also remained fragile as U.S. President Donald Trump again took aim at China, urging it to be transparent about the origins of the novel coronavirus outbreak.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Fresenius Medical Care Holdings, Inc. Frankfurt am Main, April 17, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care Holdings, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Fresenius Medical Care AG & Co. KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
The two companies and other organizations are committed to providing dialysis while limiting exposure.
Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problems in the United States who are or may be infected with coronavirus. FMC, the world's largest kidney dialysis provider, said it was collaborating with DaVita Inc., U.S. Renal Care, American Renal Associates, Satellite Healthcare and others on making a national contingency plan to ensure patients who need dialysis can continue to receive care by creating isolation capacity that other providers can use. "The companies are focused on ensuring there are enough nurses, social workers, dietitians, care technicians and available space to treat all dialysis patients, including those who are or may be infected with COVID-19, in a way that does not unnecessarily expose the hundreds of thousands of other patients who entrust them with their care," FMC said.
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. By comparison...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Fresenius Medical Care (FMC) , the world's largest kidney dialysis provider, is confident the U.S. government will soften initial targets for treating patients with kidney disease at home rather than in dedicated centres. Chief Executive Rice Powell told Reuters a goal laid out by the U.S. Department of Health and Human Services (HHS) last July for 80% of new patients to undergo dialysis at home or receive organ transplants by 2025 was under review amid industry criticism. While Fresenius is developing less bulky and easier-to-use dialysis equipment and smartphone apps for home treatment, Powell said dialysis companies risked financial penalties if they kept patients who were deemed unsuitable for home treatment in dialysis centres under the new goals.
Germany's Fresenius Medical Care <FMEG.DE> on Wednesday said quarterly adjusted operating income edged 3% higher as growth in dialysis services and products was partly offset by a negative adjustment for accounts receivable in a legal dispute in North America. The kidney dialysis provider, controlled by diversified healthcare group Fresenius SE <FREG.DE>, reaffirmed a guidance for 2020 revenue and net income to grow at a mid- to high single-digit rate in 2020, when measured without currency swings and excluding special items. Asia accounted for 11% of its total quarterly revenue of 4.58 billion euros.
Today we'll look at Fresenius Medical Care AG & Co. KGaA (ETR:FME) and reflect on its potential as an investment. To...
Let's talk about the popular Fresenius Medical Care AG & Co. KGaA (ETR:FME). The company's shares saw a decent share...
Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Medicare is set to face similar challenges in 2020. Yahoo Finance’s Brian Sozzi and Anjalee Khemlani discuss the new medicare initiatives.
Is Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their […]
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.